---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000044"
form_type: "8-K/A"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:04.372990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed

## Summary
- Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.
- Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
- Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.
- Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.
- Higher interest expense drove GAAP net loss and lower adjusted EPS.

## SEC filing metadata
- accession: 0001723128-24-000044
- form_type: 8-K/A
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/0001723128-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/amrx-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000044
- JSON: https://secwatch.observer/filing/0001723128-24-000044.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.